endometriosis
Conditions
Interventions
group A:Low-dose estradiol and dydrogesterone tablets 1 tablet per day orally
group B:Tibolone 1.25mg orally per day
Sponsors
West China Second University Hospital, Sichuan University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 45 who have not reached menopause and were diagnosed with stage III/IV endometriosis by laparoscopy (with the uterus preserved), pathologically confirmed to have endometriosis, and after comprehensive assessment by clinicians, need to receive GnRH-a treatment for 6 months. 2. Agree to receive the drug treatment in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Combined with serious cardiovascular and cerebrovascular diseases, diabetes, hypertension, liver and kidney insufficiency and other basic diseases; 2. Previous or current history of malignant tumor; 3. Presence of untreated endometrial dysplasia; 4. Patients with previous or current venous thrombosis (deep vein thrombosis, pulmonary embolism, etc.); 5. Patients with poor compliance; 6. Use of estrogen or estrogen-acting drugs within one month; 7. Long-term use of hormone drugs; 8. GnRH-a treatment was given within one month before surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Menopause Index score; | — |
Secondary
| Measure | Time frame |
|---|---|
| EQ-5D-5L score;Pittsburgh Sleep Quality Index;bone mineral density;estrogen;luteinizing hormone ;follicle-stimulating hormone;anti-mullerian hormone;The degree of pelvic pain;endometrial thickness; | — |
Countries
China
Contacts
Public ContactWang Ping
West China Second University Hospital, Sichuan University
Outcome results
None listed